Abstract
The prevalence of Alzheimer’s disease (AD) is higher among type 2 diabetes mellitus (T2DM) patients. In T2DM patients, the progression of AD is more rapid. Furthermore, several pathophysiological pathways are common to AD and T2DM. Humanin is a recently introduced, mitochondrial-derived peptide with neuroprotective effects. Humanin can alter the mechanisms involved in AD and T2DM pathogenesis. Insulin resistance as well as oxidative stress has been shown to be associated with increased amyloid deposition in brain neurons and islet beta cells. Moreover, advanced glycation end products and lipid metabolism disorders are common pathways of oxidative stress and low-grade systemic inflammation in AD and T2DM. These common pathways may explain AD and T2DM pathogenesis and suggest common treatments for both diseases. Treatments for T2DM and AD attempt to slow cognitive decline, and recent investigations have focused on agents that may alter pathways common to AD and T2DM pathogenesis. Non-steroidal antiinflammatory drugs, such as interleukin-1 antagonists and statins, are possible drug candidates for both AD and T2DM.
Keywords: Alzheimer's disease, Amyloid beta, Apo-lipoprotein E, diabetes, inflammation, oxidative stress.
CNS & Neurological Disorders - Drug Targets
Title:Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
Volume: 13 Issue: 3
Author(s): Hamidreza Mahboobi, Javad Golmirzaei, Siew H. Gan, Mehrdad Jalalian and Mohammad A. Kamal
Affiliation:
Keywords: Alzheimer's disease, Amyloid beta, Apo-lipoprotein E, diabetes, inflammation, oxidative stress.
Abstract: The prevalence of Alzheimer’s disease (AD) is higher among type 2 diabetes mellitus (T2DM) patients. In T2DM patients, the progression of AD is more rapid. Furthermore, several pathophysiological pathways are common to AD and T2DM. Humanin is a recently introduced, mitochondrial-derived peptide with neuroprotective effects. Humanin can alter the mechanisms involved in AD and T2DM pathogenesis. Insulin resistance as well as oxidative stress has been shown to be associated with increased amyloid deposition in brain neurons and islet beta cells. Moreover, advanced glycation end products and lipid metabolism disorders are common pathways of oxidative stress and low-grade systemic inflammation in AD and T2DM. These common pathways may explain AD and T2DM pathogenesis and suggest common treatments for both diseases. Treatments for T2DM and AD attempt to slow cognitive decline, and recent investigations have focused on agents that may alter pathways common to AD and T2DM pathogenesis. Non-steroidal antiinflammatory drugs, such as interleukin-1 antagonists and statins, are possible drug candidates for both AD and T2DM.
Export Options
About this article
Cite this article as:
Mahboobi Hamidreza, Golmirzaei Javad, Gan H. Siew, Jalalian Mehrdad and Kamal A. Mohammad, Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes, CNS & Neurological Disorders - Drug Targets 2014; 13 (3) . https://dx.doi.org/10.2174/1871527312666131223110147
DOI https://dx.doi.org/10.2174/1871527312666131223110147 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics New Antihypertensive Drugs Under Development
Current Medicinal Chemistry COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy for Wiskott-Aldrich Syndrome
Current Gene Therapy Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design Porphyrin Photosensitised Processes in the Prevention and Treatment of Water- and Vector-Borne Diseases
Current Medicinal Chemistry A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Recent Progress in Therapeutic and Diagnostic Applications of Lanthanides
Mini-Reviews in Medicinal Chemistry TAP-Independent MHC Class I Presentation
Current Immunology Reviews (Discontinued) Inflammation-Associated Changes in Bone Homeostasis
Inflammation & Allergy - Drug Targets (Discontinued) Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry The Antidiabetic Therapeutic Potential of Dietary Polyphenols
Current Pharmaceutical Biotechnology Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design The Normal and Pathologic Roles of the Alzheimer's β-secretase, BACE1
Current Alzheimer Research AMP-Activated Protein Kinase: Structure and Regulation
Current Protein & Peptide Science Are we Genomic Mosaics? Variations of the Genome of Somatic Cells can Contribute to Diversify our Phenotypes
Current Genomics Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Discoveries Towards Kv1.5 Potassium Channel
Current Topics in Medicinal Chemistry PET Radiotracers for Molecular Imaging in Dementia
Current Radiopharmaceuticals